CSPC feels the pain from sweeping cuts in drug prices
The pharmaceutical giant is paying the price for its aggressively low bids in China’s centralized drug tenders, as it shifts its focus from traditional to novel drugs Key Takeaway: The…
Genuine Biotech takes third shot at IPO as financial pressures mount
Demand for the company’s core product has long since faded, and sales for the product took an additional hit after the termination of a distribution partnership with Fosun Pharma Key…
China’s corporate pivots: Alibaba’s food delivery gambit and WuXi AppTec’s geopolitical hedge
Alibaba will retire the Ele.me takeout dining brand and merge it with its newer Taobao Instant Commerce. What's driving the move? And WuXi AppTec is the latest Chinese major to jump on the Middle Eastern bandwagon, with plans to potentially open a new center in Saudi Arabia. Why are a growing number of Chinese companies taking the Middle Eastern plunge?
BenQ BM takes pulse of hot Hong Kong market with new IPO bid
The private hospital operator has filed again for a Hong Kong listing, offering uninspired financials to investors after two unsuccessful attempts since last year Key Takeaways: Private hospital operator BenQ…
IPO hopeful Distinct Healthcare targets the well-to-do market
The private healthcare provider is hoping to attract investors with a business model focusing on the medical needs of affluent families in leading Chinese cities Key Takeaways: The company has…
WuXi AppTec frees up money for Middle East push
The drugs services giant has stepped up sales of non-core Chinese assets to concentrate on its international expansion, with plans for a base in Saudi Arabia Key Takeaways: The company…
So big but so what? Innovent’s license deal fails to excite investors
The Chinese biotech is selling some cancer drug rights to a Japanese pharma giant for up to $11.4 billion, pocketing a big downpayment, so why did its stock price fall?…
Recent Articles
RELATED ARTICLES
-
CSPC Pharma teases big bucks deals after earnings miss
1093.HK -
Precision cancer drugs show promise for Kelun-Biotech
6990.HK
-
Alphamab stake sale could signal harder times ahead
9966.HK
-
3SBio hits the big time with $6 billion cancer drug deal
1530.HK
-
XtalPi scores landmark deal for AI drug discovery
2228.HK
-
Rising profit at WuXi Biologics underscores drug sector rebound
2269.HK
-
Medtide launches IPO to bulk up its weight-loss business
3880.HK
